TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently resides in Beijing, China~* Diagnosis of schizophrenia or schizophreniform disorder~* Duration of symptoms is no longer than 60 months~* No history of treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days~* Current psychotic symptoms are of moderate severity or greater as measured by one of the five psychotic items in the Brief Psychiatric Rating Scale (BPRS)~Exclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV Axis I diagnosis other than schizophrenia or schizophreniform psychosis~* Documented disease of the central nervous system that might interfere with the trial assessments (e.g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic infection)~* Acute, unstable, and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension)~* A clinically significant echocardiogram (ECG) abnormality in the opinion of the investigator~* Pregnant or breastfeeding~* Use of prohibited concomitant therapy~* History of severe allergy or hypersensitivity~* Dependence on alcohol or illegal drugs~* Use of any of the following medications during the trial: antipsychotic medications other than risperidone; psychostimulants; or antidepressants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Tropisetron (Type: EXPERIMENTAL): Tropisetron (10mg/day) + risperidone(6mg/day)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + risperidone (6mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of N-Acetyl Cysteine in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients between 3.0 and 12.11 years of age inclusive~2. Males and females who are physically healthy~3. diagnosis of autism based Diagnostic and Statistical Manual (DSM-IV-TR) criteria, the Autism Diagnostic Interview-Revised, and expert clinical evaluation~4. Clinical Global Impression Severity rating of 4~5. Care provider who can reliably bring subject to clinic visits, can provide trustworthy ratings, and interacts with subject on a regular basis~6. Ability of subject to swallow the compound~7. Stable concomitant medications for at least 2 weeks~8. No planned changes in psychosocial interventions during the open-label N-Acetyl Cysteine trial~Exclusion Criteria:~1. DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified~2. Prior adequate trial of N-Acetyl Cysteine~3. Active medical problems: unstable seizures, significant physical illness (e.g., serious liver or renal pathology)~4. Pregnancy or sexually active females~5. Subjects taking antioxidant agents and glutathione prodrugs will be excluded from the study except if they have been off these compounds for at least 4 weeks

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Cysteine (Type: ACTIVE_COMPARATOR): active compound N-Acetyl Cysteine
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo or sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females (18-75 years)~* Must have been following a restrictive diet~* Diagnosis of primary hypercholesterolemia or combined dyslipidemia~Exclusion Criteria:~* Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia;~* Conditions which may cause secondary dyslipidemia.~* Uncontrolled diabetes mellitus (by hemoglobin A1c \[HbA1c\] \> 8%)~* Abnormal serum creatine kinase (CK) above the pre-specified level~* Abnormal pancreatic, liver or renal function~* Significant heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pitavastatin 2 mg (Type: EXPERIMENTAL): Pitavastatin 2 mg once daily
- Simvastatin 20 mg (Type: ACTIVE_COMPARATOR): Simvastatin 20 mg once daily
- Pitavastatin 4 mg (Type: EXPERIMENTAL): Pitavastatin 4 mg once daily
- Simvastatin 40 mg (Type: ACTIVE_COMPARATOR): Simvastatn 40 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Evaluation of Antiviral Medication in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both genders between the ages of 18-50 years~* Schizophrenia or schizoaffective disorder as defined in DSM-IV~* Duration of illness 10 years or less~* On a stable dose of an antipsychotic medication for at least a month~* Should score 4 or more on at least one of the subscales of PANSS~* Positive for HSV1~* Written informed consent~Exclusion Criteria:~* Substance abuse in the last month/dependence 6 months prior to the study~* History of, or current medical/neurological illnesses which affects CNS function e.g., epilepsy, head injury with prolonged loss of consciousness~* Pregnancy~* History of immune disorders, HIV infection or currently receiving immunosuppressants~* Subjects on regular antiviral therapy~* History of hypersensitivity to Valacyclovir~* Mental retardation as defined in DSM-IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Valacyclovir (Type: EXPERIMENTAL): 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): 2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female between the ages of 20-75 years.~2. Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control.~3. Diagnosed with type 2 diabetes mellitus.~4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL~5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable).~6. All patients give written informed consent.~Exclusion Criteria:~1. A history of hypersensitivity to statins.~2. A history of rhabdomyolysis or hereditary muscle disorders.~3. Insulin-treated patients.~4. Patient with any conditions of acute or chronic pancreatitis.~5. Creatine kinase ≧3-fold upper limit of normal (ULN).~6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1.5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT ≧3-fold ULN).~7. Overt proteinuria (repeat spot urine protein \>300mg/dl by dipstick method).~8. Patients are taking cyclosporine.~9. A history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia.~10. Patients with alcohol and drug abuse in past 3 years.~11. Serious or unstable medical or psychological conditions.~12. Hypothyroidism (TSH \> 5 μIU/mL).~13. In the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
- 2 (Type: ACTIVE_COMPARATOR): 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotherapy During Therapeutic Hypothermia to Prevent Infectious Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years-old, intubated and mechanically ventilated after out-of-hospital resuscitated cardiac arrest secondary to shockable rhythm~* Hospitalized in an ICU~* Mild therapeutic hypothermia procedure (32° to 35°C) scheduled (24 to 36 hours)~* Delay from ROSC to randomisation \< 6 hours~* Consent from family members or emergency consent~Exclusion Criteria:~* Pregnancy~* Out-of-hospital cardiac arrest secondary to non shockable rhythm and In-hospital cardiac arrest~* Need for cardiac support by cardiopulmonary bypass~* Ongoing antibiotic therapy or during the week before~* Ongoing or concomitant pneumonia~* Known chronic colonization with MRB~* Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.~* History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).~* History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid, according to the latest version of the SmPC.~* Previous lung disease~* Predictable decision of early care limitation~* Patient under guardianship or curatorship~* Moribund patient~* Participation to another trial within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amoxicillin clavulanic acid (Type: EXPERIMENTAL): Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analgesic Effects of Paracetamol/Codeine and Ibuprofen on Pain After Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy status (ASA class I);~* nonsmoker;~* not pregnant or breastfeeding;~* no medication consumption in the past 21 days;~* good oral hygiene;~* bony impaction of one mandibular third molars;~* the presence of the first and second molars;~* compliance to cooperate with the research protocol.~Exclusion Criteria:~* chronic systemic disease;~* medications with potential interaction to paracetamol-codeine or ibuprofen;~* a history of intolerance or hypersensitivity to the study drugs;~* any pre-existing pain and acute inflammatory or infectious conditions; - inability to understand or perform the study procedure.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Paracetamol/codeine Group A (Type: ACTIVE_COMPARATOR): analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
- Ibuprofen Group B (Type: ACTIVE_COMPARATOR): analgesic group preoperative oral dose of ibuprofen 400 mg
- Placebo Group C (Type: PLACEBO_COMPARATOR): Placebo group preoperative placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Giving written informed consent~* History of COPD (according to GOLD 2009) for at least 12 months prior to baseline Visit V0 associated with chronic productive cough for 3 months in each of the 2 years prior to baseline visit (with other causes of productive cough excluded)~* Age ≥ 40 years~* Forced expiratory volume after one second (FEV1)/forced vital capacity (FVC) ratio (post-bronchodilator) \< 70%~* FEV1 (post-bronchodilator) ≤ 50% of predicted~* At least two documented moderate or severe COPD exacerbations within one year prior to baseline visit~* Patients must be pre-treated with LABA and ICS for at least 12 months before baseline Visit V0. Up to 3 months before baseline Visit V0 free or fixed combinations of LABA and ICS are allowed, including changes in dose, active substances, and brands. In the last 3 months before baseline Visit V0 patients must be pre-treated with fixed combinations of LABA and ICS at a constant dose (maximum approved dosage strength of the combination).~* Former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 20 pack years~Main Exclusion Criteria:~* Exacerbations not resolved at first baseline visit~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
- Placebo (Type: PLACEBO_COMPARATOR): concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-ulcer functional dyspepsia or peptic ulcer disease~* Ability and willingness to participate in the study and to sign and give informed consent~* Confirmed H. pylori infection and with no previous treatment experience~Exclusion Criteria:~* Less than 18 years old~* With previous gastric surgery~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Triple Therapy (Type: ACTIVE_COMPARATOR): Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
- Bismuth Plus Triple Therapy (Type: EXPERIMENTAL): Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Near-infrared Fluorescence Imaging as a Supportive Tool for Localisation of Deep Infiltrating Endometriosis During Laparoscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected endometriosis with necessity for laparoscopic confirmation and resection~* Regular menstrual cycles~Exclusion Criteria:~* Patients younger than 18 years and older than 50 years at time of operation~* Subject with previous history of adverse reaction or allergy to Indocyanine Green, iodine, shellfish or iodine dyes~* Documented allergy to sulfur containing compounds~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Indocyanine Green~* Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests (Total bilirubin increased by factor 1.5 than normal and/or serum glutamic oxaloacetic transaminase increased by factor 2 than normal)~* Subject has uremia, serum creatinine (\> 2.0 mg/dl)~* Subject has severe coronary heart disease (instable angina pectoris)~* Pregnant or breast-feeding women~* Subject actively participating in another drug, biologic and/or device protocol~* The presence of medical conditions contraindicating general anesthesia or standard surgical approaches~* Subject has any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Indocyanine Green arm (Type: EXPERIMENTAL): All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.~Exclusion Criteria:~Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week wash-out period following which a baseline lipid profile will be taken at visit 2.~Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)~* Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months)~* Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to locally approved summary of product characteristics (SPC)~* HbA1c, 7.0-11.0 % (both inclusive)~* Body Mass Index (BMI), 25.0-37.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Metformin contraindication according to local practice~* Thiazolidinedione (TZD) treatment within previous 3 months prior to Visit 1~* Any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation~* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SIAC 30 (B) (Type: EXPERIMENTAL): None
- SIAC 45 (B) (Type: EXPERIMENTAL): None
- BIAsp 30 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete